INVITRO MONITORING OF CADAVER KIDNEY DONOR PRETREATMENT BY LYMPHOCYTE CULTURE
- 1 January 1976
- journal article
- research article
- Vol. 25 (3), 437-441
Abstract
Cadaver kidney donors (14) [human] were pretreated with a rapid infusion of 5 g of cyclophosphamide and 5 g of methylprednisolone to reduce graft immunogenicity by altering immunogenic passenger leucocytes. The effects of this drug infusion on peripheral lymphocytes were monitored by measuring the ability of donor lymphocytes to respond and to stimulate recipient cells in mixed lymphocyte culture and by measuring their ability to respond to phytohemagglutinin stimulation before and after infusion of the drugs. Pretreatment severely decreased the ability of donor cells to function in these tests, but the maximum effect was not seen until several hours after completion of the infusion. Donor nephrectomy should probably be delayed for at least 4 h after pretreatment to obtain maximum lymphocyte effect using this regimen. This type of in vitro testing may provide means of monitoring donor pretreatment and comparing different pretreatment protocols in human cadaveric allotransplantation.This publication has 22 references indexed in Scilit:
- The Metabolic Fate of CyclophosphamideDrug Metabolism Reviews, 1975
- ATTEMPTED IMMUNOLOGICAL ALTERATION OF CANINE RENAL ALLOGRAFT DONORSTransplantation, 1974
- THE SENSITISING PROPERTIES OF RENAL PERFUSATETransplantation, 1974
- THYMIC INFLUENCES ON CARDIAC ALLOGRAFT IMMUNOGENICITYTransplantation, 1974
- ATTEMPTED ANTIGENIC ALTERATION OF CANINE KIDNEYS BY 24− OR 48-HR PERFUSION WITH IMMUNOSUPPRESSIVE AGENTSTransplantation, 1972
- The passenger cell concept in transplantation immunologyCellular Immunology, 1971
- RENAL TRANSPLANTATION IN THE INBRED RATTransplantation, 1969
- Pathogenesis of a Local Graft versus Host Reaction: Immunogenicity of Circulating Host LeukocytesScience, 1968
- A Simplified Method for the Quantitation of in vitro Leucocyte CultureInternational Archives of Allergy and Immunology, 1968
- AN IMMUNOSUPPRESSIVE SITE OF ACTION OF HETEROLOGOUS ANTILYMPHOCYTE SERUMThe Lancet, 1967